Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus

Dapirolizumab is an investigational product in clinical development.  The safety and efficacy have not been established and it is not approved by the Food and Drug Administration, or by any health authority worldwide.  The material below is provided in response to your specific search for information on UCBCOMPASS®.  It is not intended to draw any conclusion regarding the efficacy and safety of dapirolizumab for any indication, dosage, or other claim.